Citrulline Allo. Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00751452|
Recruitment Status : Unknown
Verified January 2011 by University Hospital, Clermont-Ferrand.
Recruitment status was: Recruiting
First Posted : September 12, 2008
Last Update Posted : January 19, 2011
|Condition or disease|
30 children included. Dosage of citrullinemia on day -7, day 0 and every week up to 100 days after BMT. Histological examination and extensive infectious screening in case of persistent digestive symptoms (more than 3 days).
Two groups of patients regarding on digestive involvement. Comparison of the values of citrullinemia between these two groups.
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children|
|Study Start Date :||April 2008|
|Estimated Primary Completion Date :||September 2009|
|Estimated Study Completion Date :||September 2009|
- Citrullinemia (weekly) [ Time Frame: weekly ]
- Gastro-intestinal complications in children following allogeneic bone marrow transplantation [ Time Frame: following allogenic bone marrow transplantation ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00751452
|Contact: Lacarin Patrickemail@example.com|
|Clermont-Ferrand, France, 63003|
|Principal Investigator:||Merlin Etienne, Dr||University Hospital, Clermont-Ferrand|